Skip to content

Detection of Myocardial Dysfunction in Non-severe Subarachnoid Hemorrhage (WFNS 1-2) Using Speckle-tracking Echocardiography (STRAIN)

Detection of Myocardial Dysfunction in Non-severe Subarachnoid Hemorrhage (WFNS 1-2) Using Speckle-tracking Echocardiography (STRAIN)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03761654
Acronym
SAH-STRAIN
Enrollment
117
Registered
2018-12-03
Start date
2019-01-02
Completion date
2021-01-01
Last updated
2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Dysfunction, Stress Cardiomyopathy, Subarachnoid Hemorrhage (SAH)

Keywords

Subarachnoid Hemorrhage (SAH), Left Ventricular Dysfunction, Intensive Care Unit, Speckle-tracking, STRAIN

Brief summary

Subarachnoid hemorrhage (SAH) can cause transient myocardial dysfunction. Recently, it have been reported that myocardial dysfunctions that occur in SAH are associated with poor outcomes. It therefore appears essential to detect theses dysfunctions with the higher sensitivity as possible. Strain measurement using speckle-tracking echocardiography may detect myocardial dysfunction with great sensitivity. The main objective of this study is to assess the prevalence of myocardial dysfunction in non-severe SAH (defined by a WFNS grade 1 or 2), using speckle-tracking echocardiography. This study also aims to analyse Strain measurement with classical echocardiography and serum markers (troponin, BNP) of cardiac dysfunction.

Detailed description

Cardiac complication, occurring in the early phase of SAH has been well described. It seems that the pathophysiological mechanism involves vegetative hyperactivity due to the acute cerebral injury. It has been shown that stress cardiomyopathy is associated with delayed cerebral ischemia (DCI) and poor outcomes. Manifestations of stress cardiomyopathy are changes in electrocardiogram, release of cardiac biomarkers such as troponin and BNP, and echography evidence of impaired left ventricle ejection fraction with the use of Simpson technique and regional wall motion abnormalities. These two techniques bear intra-observer variability. A new method is available to assess left ventricular contractility at the bedside. Two-dimensional speckle-tracking images with echocardiography allows one to track a natural myocardial marker within the myocardium by standard transthoracic echocardiography. It provides unique insights into myocardial function such as tissue deformations and strain rate, which is the rate of deformation. This method is more sensitive than classical echographic left ventricular ejection fraction evaluation and bears very low interobserver variability. The Global Longitudinal Strain (GLS) is the most studied parameter. Early detection of cardiac dysfunction in SAH followed by appropriate monitoring and management may improve outcome in SAH. This is a prospective, observational and mono-center study. Patients with non-severe SAH will benefit from an echocardiography where Left Ventricular Ejection Fraction (LVEF) and GLS will be assessed on day 1, 3 and 7 following the acute injury.

Interventions

DIAGNOSTIC_TESTGlobal Longitudinal Strain measure

Global Longitudinal Strain measure on day 1 of hospitalization

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient older than 18 years * hospitalized in neuro-intensive care unit with a non-severe subarachnoid hemorrhage (WFNS 1 or 2)

Exclusion criteria

* low echogenicity * history of cardiac malformation or cardiac surgery * severe valvular heart disease * dilated cardiomyopathy * acute coronary syndrome * permanent arrythmia * patient refusal

Design outcomes

Primary

MeasureTime frameDescription
Global Longitudinal StrainDay 1 of hospitalizationIt is calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.

Secondary

MeasureTime frameDescription
Global Longitudinal StrainDay 3 of hospitalizationis calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.
Change of Left Ventricular Ejection Fraction using Simpson techniqueDays 1, 3 and 7 of hospitalization
Change in serum troponin levelDays 1, 3 and 7 of hospitalization
Change in brain natriuretic peptide (BNP) levelDays 1, 3 and 7 of hospitalization
Electrocardiogram abnormalitiesUp to day 7 of hospitalizationAbnormalities expected: * abnormal Q or QS wave (≥30 ms or a pathological R wave in V1 to V2) * ST de- pression (ST depression ≥ 0.1 mV, 80 ms post-J point) * ST elevation (ST elevation ≥ .1 mV) * peaked upright T wave (prominent peaked T wave) * T-wave inver- sion (pathologic T-wave inversion) * nonspecific ST- or T-wave changes

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026